Main Peptides

Launch Phase: Early access Pricing Sitewide
Sale!
BPC-157 + TB-500
BPC-157 + TB-500 - Image 2
, , ,

BPC-157 + TB-500

Price range: $109.99 through $209.99

Earn up to 210 points.

Complimentary Bacteriostatic Water on orders $300+ (automatically added at checkout)

- +
Add to WishlistRemove from Wishlist

Note: Shipped In Freeze Dried Lyophilized Form – Requires Bacteriostatic Water for Reconstitution (Sold Here)

Vial Size: 3 mL (Can hold up to 3 mL of BAC Water)

FREE shipping on orders $250+
Guaranteed Safe Checkout

This research formulation combines BPC-157 (5 mg) with TB500 (5 mg), a synthetic peptide fragment of thymosin beta-4. The combination is designed for studies on tissue recovery, actin regulation, and cellular repair. BPC-157 is studied for its role in angiogenesis and fibroblast activity, while TB500 supports cell motility and inflammation modulation.

Weight .06 kg
Size

10 mg, 20 mg
Shelf Life

24 months
Storage

Lyophilized: freeze at ?20 °C (?4 °F).
Reconstituted: refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Molecular Formula

C??H??N??O??

C38H68N10O14 (TB-500 fragment sequence)
PubChem CID

9941957
http://www.pubchem.ncbi.nlm.nih.gov/compound/9941957

62707662
http://www.pubchem.ncbi.nlm.nih.gov/compound/62707662
Disclaimer

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. For research purposes only. Not for human consumption.

You may also like…

  • Sale!

    KPV

     Immune Research Price range: $49.99 through $69.99
  • Sale!
    Out of stock

    CJC-1295 + Ipamorelin

     Advanced Compounds Original price was: $99.99.Current price is: $79.99.
  • Sale!

    GHK-Cu

     Immune Research Price range: $49.99 through $84.99
  • Sale!

    GLOW

     Immune Research Original price was: $199.99.Current price is: $149.99.

Your wishlist is currently empty!

Wishlist
View Wishlist

Regenerative Peptide Blend Profile

Wolverine Stack

Also known as: Wolverine Blend · BPC-157/TB-500 Stack · Healing Stack Category: Regenerative Peptide Blend Clinical Status: Preclinical (Components: Phase 1) FDA Status: Not Approved · Investigational

A synergistic peptide combination of BPC-157 and TB-500 designed to support tissue repair and regenerative processes through complementary cellular mechanisms. BPC-157 promotes angiogenesis via VEGFR2 signaling while TB-500 enhances cell migration through actin regulation. All data reflects published research findings only.

🧬

Blend Type

BPC-157 (15 aa) + TB-500 (43 aa)

🔄

Dual Pathways

VEGFR2 + Actin/ILK synergy

📚

Combined Research Base

370+ studies (200+ BPC + 170+ TB-500)

🧪

Development Stage

Preclinical · No combination trials

What Is the Wolverine Stack?

🧠 Simple Explanation

The Wolverine Stack is a combination of two research peptides — BPC-157 and TB-500 — that work through different but complementary pathways. BPC-157 (15 amino acids) was originally found in human gastric juice and promotes blood vessel formation, while TB-500 (43 amino acids, derived from Thymosin Beta-4) enhances cell migration and tissue repair. Together, they address both vascular supply and cellular mobility needed for healing.

The name references the Marvel character Wolverine, known for rapid healing. Almost all evidence comes from animal experiments — no formal combination studies in humans exist.

🔬 Advanced Context

BPC-157 (sequence: GEPPPGKPADDAGLV, MW: 1,419.5 g/mol) is a synthetic pentadecapeptide derived from human gastric juice. It operates primarily through the VEGFR2-Akt-eNOS signaling cascade, promoting angiogenesis and vascular repair. Over 200 peer-reviewed publications exist, with one Phase 1 trial (NCT02637284) completed.

TB-500 (active region: LKKTET, MW: 4,963 Da) is a synthetic 43-amino-acid fragment of Thymosin Beta-4, originally found in thymus and platelets. It works through G-actin sequestration to promote cytoskeletal remodeling and cell migration, plus ILK/Akt pathway activation for cell survival. Phase 1 human trials showed no serious adverse events at IV doses up to 1,260 mg daily for 14 days. Phase 2 trials were completed for dry eye disease.

Combination rationale: While BPC-157 brings blood supply to injury sites via VEGFR2-mediated angiogenesis, TB-500 enables repair cells to migrate to those sites via actin regulation. Both independently modulate NF-κB inflammatory signaling. No formal combination studies have been published — synergy is inferred from complementary mechanisms and independent efficacy data.

Molecular Profiles

Physicochemical characteristics of both components

BPC-157 MW

1,419.5 g/mol

TB-500 MW

4,963 Da

BPC-157 CAS

137525-51-0

TB-500 CAS

77591-33-4

BPC-157 Sequence

GEPPPGKPADDAGLV (15 aa)

TB-500 Active Region

LKKTET (actin binding)

BPC-157 Origin

Human gastric juice

TB-500 Origin

Thymus, platelets

References: PubChem CID 9941957 (BPC-157) · Expert Opin Biol Ther (TB-500)

Dual-Pathway Synergy

Two mechanisms, one goal — proposed complementary actions based on preclinical evidence

STEP 01

VEGFR2 Pathway (BPC-157)

BPC-157 activates the VEGFR2 receptor on endothelial cells, triggering the Akt-eNOS cascade. This increases nitric oxide production and promotes angiogenesis — new blood vessel formation at injury sites, ensuring adequate nutrient and oxygen delivery.

💡 Simple Translation

BPC-157 tells blood vessel cells to grow new vessels toward the injured area, like building new roads so supply trucks can reach a construction site faster.

STEP 02

G-Actin Sequestration (TB-500)

TB-500 binds to monomeric G-actin, regulating cytoskeletal remodeling. This facilitates cell motility and migration, enabling wound closure mechanisms. The active region (LKKTET) promotes cellular reorganization needed for tissue repair.

💡 Simple Translation

TB-500 helps repair cells restructure themselves internally so they can physically move toward the damaged area — like giving construction workers better tools to navigate the site.

STEP 03

ILK/Akt Cell Survival (TB-500)

TB-500 activates integrin-linked kinase (ILK), promoting Akt pathway signaling for cell survival. This supports cardiac and muscle cell migration while preventing premature cell death in damaged tissue.

💡 Simple Translation

TB-500 also sends survival signals that keep cells alive longer in hostile conditions, giving them more time to complete repairs before giving out.

STEP 04

Anti-Inflammatory Convergence (Both)

Both peptides independently modulate NF-κB inflammatory signaling, reducing pro-inflammatory cytokines and promoting resolution of inflammation. This dual anti-inflammatory action creates optimal conditions for tissue regeneration.

💡 Simple Translation

Both peptides calm down the body's alarm system in injured areas, reducing swelling and redness so that actual healing can proceed without interference.

Clinical Development Status

Current position of individual components in the regulatory pipeline

✓
Preclinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Phase 4
6
FDA Approved

No formal combination trials exist. BPC-157 Phase 1 (NCT02637284) and TB-500 Phase 1/2 trials were conducted on individual components. Neither compound is FDA approved. Both are WADA prohibited (S0 category) since 2022.

Research Timeline

Key milestones across both components of the Wolverine Stack

1991

BPC-157 Identification

BPC-157 first characterized from human gastric juice at the University of Zagreb, Croatia

1999

TB-500 Wound Healing

Thymosin Beta-4 shown to accelerate wound healing, increasing keratinocyte migration 200–300%

2004

TB-500 Cardiac Repair

Nature publishes ILK activation findings — TB-500 promotes cardiac cell migration and survival

2010

TB-500 Phase 1 Trial

Phase 1 safety trial completed: no serious adverse events at IV doses up to 1,260 mg in 56 subjects

2011

BPC-157 Tendon Evidence

Published findings on fibroblast outgrowth (+85%) and cell migration (+70%) in tendon models

2017

BPC-157 VEGFR2 Mechanism

Pro-angiogenic activity linked to VEGFR2 activation and Akt-eNOS signaling cascade

2022

WADA Prohibition

Both BPC-157 and TB-500 added to WADA S0 prohibited substance list

2025

Combined Review Published

GlobalRPH publishes comprehensive review of BPC-157 + TB-500 synergy; HSS Journal systematic review of 36 BPC-157 studies

What Does the Research Show?

Summary of investigational findings from individual component studies

📊Component Efficacy (Preclinical)
  • BPC-157: Cell migration +70% faster in tendon fibroblasts
  • TB-500: Re-epithelialization 61% faster vs saline controls
  • TB-500: Keratinocyte migration increased 200–300%
  • BPC-157: Tendon fibroblast outgrowth +85% increase
📈Research Milestones
  • 370+ combined peer-reviewed publications (200+ BPC + 170+ TB-500)
  • 2025 systematic review synthesized 36 BPC-157 studies (1993–2024)
  • TB-500 Phase 1 completed: no serious adverse events at 42–1,260 mg IV
  • TB-500 Phase 2 completed for dry eye disease indication
🔬Synergistic Potential
  • BPC-157 supplies blood vessels (VEGFR2); TB-500 brings cells (actin regulation)
  • Both independently reduce NF-κB inflammatory signaling
  • BPC-157: angiogenesis pathway; TB-500: cell motility pathway
  • Convergent effects on tissue repair from complementary molecular targets
🧪Combined Safety Profile
  • BPC-157: No lethal dose (LD50) achieved in toxicology studies
  • TB-500: Zero serious adverse events in Phase 1 human trials
  • No organ toxicity detected for either component in chronic exposure
  • Theoretical angiogenic concerns regarding tumor growth remain unstudied

Published Findings

Peer-reviewed studies on individual components with linked sources

StudyModelKey FindingYearSource
BPC-157 tendon healing promotionAnimal (Rat)Dose-dependent increase in fibroblast outgrowth, cell migration (+70%), and survival under oxidative stress2011J Applied Physiology ↗
TB-500 wound healing accelerationAnimal (Rat)61% faster re-epithelialization, 200–300% increase in keratinocyte migration vs saline controls1999J Invest Dermatol ↗
TB-500 ILK activation & cardiac repairAnimal (Mouse)Activated integrin-linked kinase, promoted cardiac cell migration, survival, and repair after myocardial infarction2004Nature ↗
BPC-157 VEGFR2 activation & angiogenesisAnimal (Rat)Upregulated VEGFR2 expression, enhanced receptor internalization, activated Akt-eNOS signaling cascade2017J Mol Medicine ↗
TB-500 Phase 1 safety trialHuman (n=56)No serious adverse events at IV doses of 42–1,260 mg daily for 14 days; 100% completion rate2010Ann NY Acad Sci ↗
BPC-157 vasomotor tone & eNOS signalingAnimal (Rat)Modulatory effects on vasomotor tone through Src-Cav-1-eNOS pathway interaction2020Nature Sci Reports ↗
Orthopaedic sports medicine review (BPC-157)Systematic Review (36)Positive outcomes in 92% of musculoskeletal models; 7/12 patients reported pain relief >6 months2025HSS Journal ↗
BPC-157 & TB-500 combined reviewClinical ReviewComplementary mechanisms: VEGFR2/angiogenesis + actin/cell migration; convergent anti-inflammatory effects2025GlobalRPH ↗
Human (n=56)2010

TB-500 Phase 1 safety trial

No serious adverse events at IV doses 42–1,260 mg; 100% completion

View Source ↗
Systematic Review2025

Orthopaedic sports medicine review (36 studies)

Positive outcomes in 92% of musculoskeletal models; 7/12 pain relief >6 months

View Source ↗
Animal (Rat)2011

BPC-157 tendon healing promotion

Fibroblast outgrowth, cell migration (+70%), survival under oxidative stress

View Source ↗
Animal (Mouse)2004

TB-500 ILK activation & cardiac repair

Activated ILK, promoted cardiac cell migration and survival after myocardial infarction

View Source ↗
Clinical Review2025

BPC-157 & TB-500 combined review

Complementary mechanisms: VEGFR2/angiogenesis + actin/cell migration; convergent anti-inflammatory effects

View Source ↗

⚠️ No formal combination studies have been published. Synergy is inferred from complementary mechanisms. The majority of listed studies are preclinical.

Research Applications

Areas of active investigation for individual and combined components

  • BPC-157: Investigated in VEGFR2-mediated angiogenesis and vascular repair pathways
  • TB-500: Studied in actin-mediated cell migration and cytoskeletal remodeling
  • Combined: Explored for musculoskeletal tissue healing — tendon, ligament, muscle, and bone
  • TB-500: Evaluated in cardiac protection via ILK activation and cardiomyocyte migration
  • BPC-157: Examined in gastrointestinal cytoprotection and ulcer prevention models
  • TB-500: Investigated in neurological recovery — oligodendrogenesis and myelination enhancement
  • Both: Assessed for anti-inflammatory effects through NF-κB pathway modulation
  • Combined: Studied for complementary wound healing — vascular supply (BPC) + cellular mobility (TB-500)

Delivery Methods Studied in Research

Investigational administration routes evaluated for individual components

Subcutaneous Injection

Most commonly studied route; allows localized delivery near injury site for both components

Intramuscular Injection

Used in select musculoskeletal injury models for both BPC-157 and TB-500

Intravenous Infusion

TB-500 Phase 1 used IV at 42–1,260 mg; BPC-157 pilot evaluated 10–20 mg IV

Oral Administration

Investigated for BPC-157 due to its unusual 24+ hour stability in gastric acid

Intraperitoneal Injection

Frequently used in rodent models for systemic absorption studies of both peptides

Why It Arrives as a Powder

Understanding lyophilized formulation in research peptides

❄️

Stability Preservation

Lyophilization removes water content, significantly reducing the rate of chemical degradation that occurs in liquid solutions, preserving structural integrity during storage and transport.

📅

Extended Shelf Life

Dry powder form can maintain potency at -20°C for extended periods, far exceeding the approximately 30-day window available for reconstituted liquid preparations.

🛡️

Degradation Prevention

Peptide bonds are susceptible to hydrolysis in aqueous environments. Removing the solvent eliminates this primary degradation pathway, reducing fragmentation and loss of biological activity.

🔬

Laboratory Preparation Standards

Reconstitution in research settings follows established protocols using bacteriostatic water or sterile saline, allowing precise concentration control for the specific experimental design.

✅

Sterile Research Conditions

Lyophilized preparations are typically processed under controlled, low-bioburden environments. Proper aseptic technique during reconstitution maintains the sterility required for reliable research outcomes.

Transparency & Quality Verification

Analytical standards applied to research-grade peptide materials

🧪

Third-Party Analytical Testing

Independent laboratories perform comprehensive analysis on each production batch, ensuring unbiased verification of compound identity and purity.

📊

Purity Verification (HPLC)

High-Performance Liquid Chromatography confirms peptide purity levels, typically targeting ≥98% for research-grade material.

🔬

Identity Confirmation (Mass Spec)

Mass spectrometry validates molecular weight and structural identity, confirming the compound matches its expected profile for each component.

📋

Batch-Specific Certificates

Each lot is accompanied by a unique COA detailing purity percentage, lot number, test date, labeled vs. actual content, and testing laboratory.

📁

Documentation Transparency

All analytical results, testing methodologies, and laboratory credentials are made available for researcher review and institutional compliance.

🌡️

Storage Verification Standards

Cold-chain integrity monitoring ensures proper temperature maintenance from production through delivery, preserving compound stability.

Related Peptides

Individual components and related multi-peptide blends

BPC-157

Regenerative Peptide

VEGFR2 angiogenesis & tissue repair

TB-500

Regenerative Peptide

Actin regulation & cell migration

GHK-Cu

Copper Peptide

Skin remodeling & wound healing

KPV

Anti-Inflammatory

Immune modulation & gut health

GLOW Protocol

Peptide Blend

BPC-157 + TB-500 + GHK-Cu

KLOW Blend

Peptide Blend

BPC-157 + TB-500 + GHK-Cu + KPV

Frequently Asked Questions

Investigational context for common inquiries about the Wolverine Stack

The Wolverine Stack is a combination of two regenerative research peptides: BPC-157 (Body Protection Compound-157, 15 amino acids from gastric juice) and TB-500 (a synthetic fragment of Thymosin Beta-4, 43 amino acids from thymus). The name references the Marvel character Wolverine, known for rapid healing. BPC-157 promotes blood vessel formation (angiogenesis) through VEGFR2 signaling, while TB-500 enhances cell migration through actin regulation. Together, they address both vascular supply and cellular mobility needed for tissue repair.
No formal clinical trials have been published specifically on the BPC-157 + TB-500 combination. The synergistic potential is inferred from their complementary mechanisms of action and independent efficacy data. BPC-157 has over 200 preclinical studies and one Phase 1 trial, while TB-500 has completed Phase 1 and Phase 2 trials for different indications. A 2025 GlobalRPH review examined the combined rationale based on convergent effects on angiogenesis and inflammation through distinct molecular targets.
BPC-157 primarily works through the VEGFR2-Akt-eNOS pathway to promote angiogenesis (blood vessel formation), while TB-500 primarily works through G-actin sequestration to promote cell migration and cytoskeletal remodeling. For tissue repair, you need both: blood vessels to supply nutrients and oxygen (BPC-157), and cells that can migrate to the injury site (TB-500). Both peptides also independently modulate NF-κB inflammatory pathways, reducing chronic inflammation's damaging effects on healing tissues.
Both peptides individually have demonstrated favorable safety profiles. BPC-157 has no established lethal dose (LD50) in preclinical studies and shows no organ toxicity. TB-500 Phase 1 trials showed no serious adverse events at IV doses up to 1,260 mg daily for 14 days with 100% completion rate. However, no combination safety studies exist, and both peptides promote angiogenesis, which theoretically could affect tumor growth. Neither peptide is FDA approved. Possible side effects reported include injection site reactions, mild headache, fatigue, and nausea.
Both peptides have been administered via multiple routes: subcutaneous injection (most common), intramuscular injection, intravenous infusion, and intraperitoneal injection (in animal models). BPC-157 is notably stable in gastric juice for 24+ hours, supporting oral administration. TB-500 Phase 1 trials used IV administration. There are no established combination protocols — researchers typically derive dosing from individual peptide studies.
Neither BPC-157 nor TB-500 is FDA approved for human therapeutic use. They are classified as unapproved drugs by the FDA. Both are banned by WADA (World Anti-Doping Agency) under category S0 (non-approved substances) since 2022, and BPC-157 is on the DoD Prohibited Dietary Supplement list. They are prescription-only in Australia and New Zealand. They may be available for research purposes in some jurisdictions, but this does not imply safety or efficacy for human use.
BPC-157 preclinical dosing typically ranged between 10 ng/kg and 10 μg/kg body weight in animal models. TB-500 Phase 1 trials evaluated IV doses of 42–1,260 mg daily. Common commercial blend formulations contain BPC-157 10 mg + TB-500 10 mg per vial. No standardized human dosing protocol exists.
The lack of regulatory oversight means purity, potency, sterility, and batch-to-batch consistency may vary significantly between suppliers. Certificates of analysis (COAs) should be evaluated, and products from reputable sources with third-party HPLC and mass spectrometry testing are recommended. Contamination with other substances or inaccurate dosing are real concerns with non-pharmaceutical grade products. Note: Many vendors mislabel Thymosin Beta-4 as 'TB-500' in premixed products.
In lyophilized (powder) form, both peptides should be stored at -20°C for optimal long-term stability. Once reconstituted, refrigerate at 2–8°C and use within approximately 30 days. BPC-157 demonstrates remarkable stability, maintaining integrity in gastric juice for 24+ hours. Both compounds should be protected from light and kept sealed until preparation.
Both peptides promote angiogenesis (new blood vessel growth), raising theoretical concerns about potential effects on tumor development in individuals with undiagnosed malignancies — a risk that has not been formally studied. Long-term human safety data does not exist for either compound. The effects of extended exposure, drug interactions, and impact on specific populations (pregnancy, elderly, immunocompromised) remain entirely unknown. Combining two substances with incomplete safety profiles compounds the uncertainty.

Sources & References

BPC-157 and TB-500: Background, Indications, Efficacy, and Safety ↗

McAuley D · GlobalRPH (2025)

Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review ↗

Vasireddi N et al. · HSS Journal (2025) · DOI: 10.1177/15563316251355551

The promoting effect of pentadecapeptide BPC 157 on tendon healing ↗

Chang CH et al. · Journal of Applied Physiology (2011) · DOI: 10.1152/japplphysiol.00945.2010

Thymosin beta4 accelerates wound healing ↗

Malinda KM et al. · Journal of Investigative Dermatology (1999) · DOI: 10.1046/j.1523-1747.1999.00708.x

Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair ↗

Bock-Marquette I et al. · Nature (2004) · DOI: 10.1038/nature03000

A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers ↗

Ruff D et al. · Annals of the New York Academy of Sciences (2010) · DOI: 10.1111/j.1749-6632.2010.05474.x

Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications ↗

Goldstein AL et al. · Expert Opinion on Biological Therapy (2012) · DOI: 10.1517/14712598.2012.634793

Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation ↗

Hsieh MJ et al. · Journal of Molecular Medicine (2017) · DOI: 10.1007/s00109-016-1488-y

Modulatory effects of BPC 157 on vasomotor tone and the Src-Cav-1-eNOS signaling pathway ↗

Hsieh MJ et al. · Scientific Reports (Nature) (2020) · DOI: 10.1038/s41598-020-74022-y

Progress on the Function and Application of Thymosin β4 ↗

Xing Y et al. · International Journal of Molecular Sciences (2021) · DOI: 10.3390/ijms222413136

Preclinical safety evaluation of body protective compound-157 ↗

Xu C et al. · Regulatory Toxicology and Pharmacology (2020) · DOI: 10.1016/j.yrtph.2020.104665

PCO-02 — Safety and Pharmacokinetics Trial (Phase 1) ↗

ClinicalTrials.gov (2015) · NCT02637284

⚠️ Important Notice

For laboratory research use only. This information is not intended to diagnose, treat, cure, or prevent any disease.

All information presented on this page is derived from peer-reviewed literature and is provided exclusively for educational and scientific reference purposes. Nothing on this page constitutes medical advice, personal recommendations, or encouragement of any kind.

Search
Shopping Cart
BPC-157 + TB-500
10 mg
20 mg
Price range: $109.99 through $209.99
−
+